Pfizer, Oxford COVID-19 vaccines reduces severity of the disease in elderly: pre-print study

Symptomatic COVID-19 infections in those 70+ years of age also decreased, three weeks after a single shot of either vaccine was given.

Press Trust of India March 03, 2021 09:16:15 IST
Pfizer, Oxford COVID-19 vaccines reduces severity of the disease in elderly: pre-print study

Image: Pixabay

The Pfizer and Oxford-AstraZeneca vaccines for COVID-19 are highly effective in reducing severe coronavirus infection among people aged 70 years and above, according to a study. The research, posted as a pre-print and yet to be peer-reviewed, estimated the effect of both the COVID-19 vaccines on laboratory confirmed symptomatic disease in individuals aged 70 years or older in England. The researchers, including those from Public Health England (PHE), compared the rate of hospitalisation and deaths in confirmed COVID-19 patients aged over 80 who were vaccinated more than 14 days before testing positive, with unvaccinated cases.

Data suggests that in the over 80s, a single dose of either vaccine is more than 80 percent effective at preventing hospitalisation, around 3 to 4 weeks after the jab, PHE said in a statement. Evidence for the Pfizer vaccine suggests that it leads to 83 percent reduction in deaths from COVID-19 , it said.

The data also shows symptomatic infections in over 70s decreased from around three weeks after one dose of both vaccines.

Pfizer Oxford COVID19 vaccines reduces severity of the disease in elderly preprint study

A nurse holds a vial of the Pfizer-BioNTech COVID-19 vaccine at Guy's Hospital in London, Tuesday, Dec. 8, 2020, as the U.K. health authorities rolled out a national mass vaccination program. Image credit: AP Photo/Frank Augstein

"Vaccination with either a single dose of Pfizer or Oxford-AstraZeneca COVID-19 vaccination was associated with a significant reduction in symptomatic SARS-CoV2 positive cases in older adults with even greater protection against severe disease," said the authors of the study, adding both the vaccines show similar effects.

They said the protection was maintained for the duration of over six weeks of follow-up, and there is a clear effect of both the vaccines against the UK variant of concern.

Experts say the new analysis adds to growing evidence that the vaccines are working, and are highly effective in protecting people against severe illness, hospitalisation and death.

"This adds to growing evidence showing that the vaccines are working to reduce infections and save lives," Mary Ramsay, PHE Head of Immunisation, said in the statement.

"While there remains much more data to follow, this is encouraging and we are increasingly confident that vaccines are making a real difference," Ms Ramsay said.

However, she cautioned that the protection is not complete and it is not known yet how much these vaccines will reduce the risk of someone passing the coronavirus onto others.

"Even if you have been vaccinated, it is really important that you continue to act like you have the virus, practise good hand hygiene and stay at home," Ms Ramsay added.

Updated Date:

also read

WTO says recovery of global trade in 2021 hinges on widespread COVID-19 vaccination
World

WTO says recovery of global trade in 2021 hinges on widespread COVID-19 vaccination

While the rebound this year will be stronger than expected, WTO's growth forecast states it could slow to 4 percent in 2022.

Coronavirus LIVE Updates: Maharashtra records 58,952 new COVID-19 cases, 278 deaths; tally now 35.7 lakh
India

Coronavirus LIVE Updates: Maharashtra records 58,952 new COVID-19 cases, 278 deaths; tally now 35.7 lakh

Coronavirus LIVE Updates:In view of an alarming rise in cases, the state government has announced a 15-day-long stricter measures which came into force at 8 pm on Wednesday and will remain in operation till 7 am on 1 May

Amid blood clot scares, COVAX says it backs AstraZeneca's COVID-19 vaccine
World

Amid blood clot scares, COVAX says it backs AstraZeneca's COVID-19 vaccine

Covax's first wave intended to distribute some 238.2 mn doses to 142 countries, out of which 237 mn were AstraZeneca doses.